Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2025 | $19.00 → $17.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/31/2025 | $18.00 → $15.00 | Neutral → Sell | Citigroup |
| 12/3/2024 | $16.00 | Sell | Goldman |
| 8/30/2024 | $19.50 | Neutral | UBS |
| 1/29/2024 | $23.00 | Neutral | Citigroup |
| 1/22/2024 | $20.50 → $23.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/13/2023 | $16.50 → $20.50 | Equal-Weight → Overweight | Morgan Stanley |
| 4/8/2022 | $18.00 → $19.00 | Neutral → Outperform | Credit Suisse |
Impressive Adjusted EBITDA Margin Expansion Expressive Cash Generation First Dividend Announcement Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2024. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2024 Highlights 4Q24 Net Revenue increased 16.3% YoY to R$849.0 million. Net Revenue excluding acquisitions increased 12.0%, reaching R$817.8 million. 4Q24 Adjust
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), Brazil's leading medical education group and provider of medical practice solutions, announced that its board of directors (the "Board") approved its first distribution of a cash dividend. On March 12, 2025, Afya's Board declared a cash dividend of R$129.8 million, representing 20% of the Company's consolidated net income of R$648.9 million for the year ended December 31, 2024. This amounts to a dividend per share (DPS) of R$1.348923, payable in U.S. dollars on April 4, 2025, to shareholders of record as of the close of business on March 26, 2025. The payment will be made at the exchange rate (PTAX) published on March 13, 2
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it has entered into a share purchase agreement for the acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of Faculdade Masterclass Ltda. ("Faculdade Única de Contagem" or "FUNIC"), present in Contagem (MG). The acquisition will add 60 medical school seats to Afya in Contagem, a city in the metropolitan area of Belo Horizonte, the capital of Minas Gerais. FUNIC is pre-operational, with leased real estate prepared for the start of the medical school operation. I
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
Morgan Stanley downgraded Afya from Equal-Weight to Underweight and set a new price target of $17.00 from $19.00 previously
Citigroup downgraded Afya from Neutral to Sell and set a new price target of $15.00 from $18.00 previously
Goldman initiated coverage of Afya with a rating of Sell and set a new price target of $16.00
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today announces that its clinical decision software, WhiteBook, an app created by PEBMED, was ranked as one of the 10 Top Apps in Brazil by consumer spend in 2020 for the fifth year in a row. App Annie conducted the study, a website specialized in app analytics and app market data that combined data from iOS and Google Play that evaluates more than 8 million mobile app per year. In the top ten WhiteBook was among great apps such as Tinder, YouTube, Netflix, TikTok and others. Whitebook is a mobile and web application software that helps doctors and medical students to make
Impressive Adjusted EBITDA Margin Expansion Expressive Cash Generation First Dividend Announcement Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2024. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2024 Highlights 4Q24 Net Revenue increased 16.3% YoY to R$849.0 million. Net Revenue excluding acquisitions increased 12.0%, reaching R$817.8 million. 4Q24 Adjust
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), Brazil's leading medical education group and provider of medical practice solutions, announced that its board of directors (the "Board") approved its first distribution of a cash dividend. On March 12, 2025, Afya's Board declared a cash dividend of R$129.8 million, representing 20% of the Company's consolidated net income of R$648.9 million for the year ended December 31, 2024. This amounts to a dividend per share (DPS) of R$1.348923, payable in U.S. dollars on April 4, 2025, to shareholders of record as of the close of business on March 26, 2025. The payment will be made at the exchange rate (PTAX) published on March 13, 2
Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Expressive Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and nine-month periods ended September 30, 2024 (third quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2024 Highlights 3Q24 Net Revenue increased 16.3% YoY to R$841.2 million. Net Revenue excluding acquisitions grew 11.8%, reaching R$808.8 million. 3Q24 Ad
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)